Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$7.02 - $13.33 $483,460 - $918,023
-68,869 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$11.32 - $16.63 $15,644 - $22,982
1,382 Added 2.05%
68,869 $785,000
Q2 2021

Aug 16, 2021

SELL
$15.16 - $18.97 $11,354 - $14,208
-749 Reduced 1.1%
67,487 $1.08 Million
Q1 2021

May 17, 2021

BUY
$13.12 - $20.9 $631,937 - $1.01 Million
48,166 Added 239.99%
68,236 $1.22 Million
Q4 2020

Feb 16, 2021

SELL
$9.12 - $14.49 $251,894 - $400,213
-27,620 Reduced 57.92%
20,070 $271,000
Q3 2020

Nov 16, 2020

BUY
$10.46 - $14.46 $36,986 - $51,130
3,536 Added 8.01%
47,690 $561,000
Q2 2020

Aug 14, 2020

BUY
$12.0 - $16.13 $119,544 - $160,687
9,962 Added 29.14%
44,154 $652,000
Q1 2020

May 15, 2020

BUY
$11.84 - $25.52 $404,833 - $872,579
34,192 New
34,192 $462,000

Others Institutions Holding AERI

About AERIE PHARMACEUTICALS INC


  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Cushing Asset Management, LP Portfolio

Follow Cushing Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cushing Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cushing Asset Management, LP with notifications on news.